Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Conditions
Brief summary
This clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and specific plan for each patient to make changes in their daily lives. These may include changes to their diet, sleep, activity, medicines, or even referrals to other providers depending on the patient's needs. Studying survival and quality of life in patients over 60 receiving an allogeneic hematopoietic cell transplant may help identify the effects of treatment.
Detailed description
PRIMARY OBJECTIVE: I. To demonstrate that geriatric assessment with management (GAM) intervention will lead to improved physical functioning in allogeneic hematopoietic cell transplant (allo-HCT)-eligible older adults as measured by improvement in 6-Minute Walk Test distance of at least 35 meters. SECONDARY OBJECTIVES: I. To demonstrate that GAM intervention will result in improvement in Short Physical Performance Battery score by at least 1 point or score will remain \>= 10 for those with baseline scores \>= 10. II. To demonstrate that GAM intervention will result in improvement in Mini Nutritional Assessment score by at least 2 points or score will remain \>= 12 for those with baseline scores \>= 12. III. To evaluate change in cognition and mental health as measured by Montreal Cognitive Assessment, Personal Health Questionnaire-9, Generalized Anxiety Disorder-7, and Transplant Evaluation Rating Scale score before and after GAM intervention. IV. To determine cumulative incidence rate for receipt of allo-HCT among study participants. V. To measure overall survival and non-relapse mortality among study participants. VI. To assess self-reported adherence to prescribed interventions. VII. To measure change in patient-reported quality of life immediately following GAM intervention and up to one year after completion of intervention. EXPLORATORY OBJECTIVES: I. To describe patterns of sleep and activity among study participants during intervention period based on accelerometer data. II. To understand transplant physician rationale for not proceeding to allo-HCT for older patients with eligible diagnoses. OUTLINE: Patients undergo personalized Geriatric Optimization (GO!) plan consisting of study visits over 50 minutes at baseline and 6 months after first visit or at the time of hospital admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant. Patients complete questionnaires once a month for up to 6 months and wear an accelerometer for up to 6 months.
Interventions
OTHERHealth Promotion and Education
Undergo GO!
OTHERMedical Device Usage and Evaluation
Wear accelerometer
OTHERQuality-of-Life Assessment
Complete quality of life assessments and diary entries
OTHERQuestionnaire Administration
Complete questionnaires
Sponsors
Ohio State University Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 60 years * Diagnosed with hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplantation. This includes acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelofibrosis, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and aplastic anemia. Disease specific eligibility for allo-HCT to be determined by treating physician * Must be able to understand written and spoken English * Must be willing to attend all study visits and comply with study procedures for the entire length of the study
Exclusion criteria
* Documented history of dementia * No possibility of proceeding to allogeneic hematopoietic cell transplant within the next 6 months as determined by treating physician * Scheduled admission for allogeneic hematopoietic cell transplant within 30 days of enrollment * Inability or unwillingness to give written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in 6-Minute Walk Test distance | At 6 months before transplant, up to 12 months after transplant | Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Short Physical Performance Battery score | At 6 months before transplant, up to 12 months after transplant | Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools. |
| Change in in Mini Nutritional Assessment score | At 6 months before transplant, up to 12 months after transplant | Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools. |
| Change in cognitive and mental health | At 6 months before transplant, up to 12 months after transplant | Measured by Montreal Cognitive Assessment Generalized Anxiety Disorder-7. Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools. |
| Proportion of sample achieving "normal" scores on geriatric assessment tools | At 6 months before transplant, up to 12 months after transplant | McNemar test will be used to compare proportion of sample achieving normal scores on geriatric assessment tools. |
| Time to receipt of transplant | Up to 1 year after treatment | Estimates of cumulative incidence of receipt of transplant with 95% confidence intervals will be provided for 100 days and one-year after end of treatment. |
| Overall survival | Up to 12 months after transplant | Overall survival will be defined as the period from date of baseline assessment to death from any cause. Date of death will be confirmed by chart review. Will be estimated utilizing Kaplan-Meier method. |
| Non-relapse mortality | Up to 12 months after transplant | Non-relapse mortality will be defined as the period from date of baseline assessment to death without evidence of relapsed primary hematologic disease. Relapse will be treated as competing risk. Documentation of date of relapse will be confirmed by chart review and collaboration with transplant physician if necessary. Estimates of cumulative incidence of non-relapse mortality with 95% confidence intervals will be provided for 100 days and one-year after end of treatment. |
| Adherence to prescribed geriatric optimization plan (GO!) prescription | Up to 6 months after transplant | Will be assessed by self-report through monthly survey during intervention and at end-of-treatment assessment. Participants will be asked to estimate monthly frequency of completing all items in GO! prescription and this information will be collected through REDCap survey. Due to self-report nature of this item, no specific definition of adherence is offered beyond that which is asked of participants. |
| Change in quality of life | At 6 months before transplant, 3, and 6 month after transplant | Assessed with European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Elderly Cancer Patients Module. Wilcoxon signed rank test or McNemar test will be used to assess the change over time. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSarah Wall, MD
Ohio State University Comprehensive Cancer Center
Outcome results
None listed